
## Stefan O Ciurea

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1723667/publications.pdf Version: 2024-02-01



STEEAN O CHIDEA

#	Article	IF	CITATIONS
1	Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia, 2022, 36, 155-164.	3.3	43
2	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Advances, 2022, 6, 486-494.	2.5	25
3	Number of HLA-Mismatched Eplets Is Not Associated with Major Outcomes in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study. Transplantation and Cellular Therapy, 2022, 28, 107.e1-107.e8.	0.6	5
4	Stability of Captisol-enabled versus propylene glycol–based melphalan at room temperature and after refrigeration. American Journal of Health-System Pharmacy, 2022, , .	0.5	0
5	Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nature Communications, 2022, 13, 2228.	5.8	14
6	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplantation and Cellular Therapy, 2022, 28, 681-693.	0.6	13
7	Can we cure refractory Hodgkin's lymphoma with transplantation?. Bone Marrow Transplantation, 2021, 56, 278-281.	1.3	2
8	Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematologica, 2021, 144, 74-81.	0.7	2
9	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplantation and Cellular Therapy, 2021, 27, 68,e1-68,e9.	0.6	15
10	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. Cancer, 2021, 127, 609-618.	2.0	12
11	Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer, 2021, 127, 1598-1605.	2.0	9
12	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood, 2021, 137, 3291-3305.	0.6	85
13	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 272.e1-272.e5.	0.6	12
14	Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplantation and Cellular Therapy, 2021, 27, 430.e1-430.e7.	0.6	18
15	Incidence and impact of community respiratory viral infections in postâ€transplant cyclophosphamideâ€based graftâ€ <i>versus</i> å€host disease prophylaxis and haploidentical stem cell transplantation. British Journal of Haematology, 2021, 194, 145-157.	1.2	12
16	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplantation and Cellular Therapy, 2021, 27, 913.e1-913.e12.	0.6	6
17	Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation. Haematologica, 2021, , .	1.7	6
18	Treatment of allosensitized patients receiving allogeneic transplantation. Blood Advances, 2021, 5, 4031-4043.	2.5	32

#	Article	IF	CITATIONS
19	Mismatch in SIRPα, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Advances, 2021, 5, 3407-3417.	2.5	3
20	Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplantation, 2021, 56, 1316-1324.	1.3	18
21	Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 1779-1779.	0.6	Ο
22	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 12-24.	1.3	94
23	Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 197-203.	2.0	16
24	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 665-671.	2.0	21
25	Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation. Blood Advances, 2020, 4, 3474-3485.	2.5	13
26	Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica, 2020, 106, 269-274.	1.7	10
27	Transforming growth factor βâ€mediated micromechanics modulates disease progression in primary myelofibrosis. Journal of Cellular and Molecular Medicine, 2020, 24, 11100-11110.	1.6	11
28	<scp>NK</scp> cell alloreactivity in acute myeloid leukemia in the postâ€ŧransplant cyclophosphamide era. American Journal of Hematology, 2020, 95, 1590-1598.	2.0	7
29	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. Blood Advances, 2020, 4, 2073-2083.	2.5	39
30	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biology of Blood and Marrow Transplantation, 2020, 26, 1439-1445.	2.0	17
31	Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL. Blood, 2020, 136, 1786-1789.	0.6	40
32	Recent Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, e215-e221.	2.0	23
33	Haploidentical transplants for patients with graft failure after the first allograft. American Journal of Hematology, 2020, 95, E267.	2.0	5
34	Haploidentical transplants for patients with relapse after the first allograft. American Journal of Hematology, 2020, 95, 1187.	2.0	6
35	Significance of minimal residual disease monitoring by realâ€time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer, 2020, 126, 2183-2192.	2.0	17
36	Validation of a Hematopoietic Cell Transplant-Composite Risk (HCT-CR) Model for Post-Transplant Survival Prediction in Patients with Hematologic Malignancies. Clinical Cancer Research, 2020, 26, 2404-2410.	3.2	9

#	Article	IF	CITATIONS
37	Donorâ€specific antiâ€HLA antibodies and …recipientâ€specific antiâ€HLA antibodies? The conundrum on pregnancy in transplantation. American Journal of Hematology, 2020, 95, E128-E130.	2.0	2
38	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer, 2020, 126, 2193-2205.	2.0	33
39	Endothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1013-1020.	2.0	34
40	Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. Blood, 2020, 135, 449-452.	0.6	39
41	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Advances, 2020, 4, 1296-1306.	2.5	7
42	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica, 2020, 105, 47-58.	1.7	51
43	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 1459-1468.	2.0	35
44	What the Intensivist Needs to Know About Hematopoietic Stem Cell Transplantation?. , 2020, , 1531-1546.		2
45	Haploidentical Mbil-21 <i>Ex Vivo</i> Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia. Blood, 2020, 136, 11-12.	0.6	1
46	Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types. Blood, 2020, 136, 20-21.	0.6	0
47	Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. Blood, 2020, 136, 23-24.	0.6	0
48	Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 24-25.	0.6	1
49	Who is the best donor for haploidentical stem cell transplantation?. Seminars in Hematology, 2019, 56, 194-200.	1.8	15
50	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. Leukemia and Lymphoma, 2019, 60, 3536-3543.	0.6	11
51	Sequential kidney and allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2019, 94, E267-E270.	2.0	1
52	Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. American Journal of Hematology, 2019, 94, 1382-1387.	2.0	20
53	Considerations for haploidentical versus unrelated donor transplants. Bone Marrow Transplantation, 2019, 54, 738-742.	1.3	5
54	HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Current Research in Translational Medicine, 2019, 67, 51-55.	1.2	13

#	Article	IF	CITATIONS
55	Cellular therapy for acute myeloid Leukemia – Current status and future prospects. Blood Reviews, 2019, 37, 100578.	2.8	49
56	Curative potential of hematopoietic stem cell transplantation for advanced psoriasis. American Journal of Hematology, 2019, 94, E176-E180.	2.0	5
57	Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biology of Blood and Marrow Transplantation, 2019, 25, 1347-1354.	2.0	4
58	Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematology,the, 2019, 6, e266-e275.	2.2	68
59	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 1340-1346.	2.0	7
60	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Advances, 2019, 3, 360-369.	2.5	92
61	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Advances, 2019, 3, 1826-1836.	2.5	89
62	Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Advances, 2019, 3, 1858-1867.	2.5	25
63	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 480-487.	2.0	10
64	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biology of Blood and Marrow Transplantation, 2019, 25, 1039-1044.	2.0	11
65	Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 601-606.	1.3	24
66	Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. Biology of Blood and Marrow Transplantation, 2019, 25, 335-342.	2.0	20
67	Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplantation, 2019, 54, 839-848.	1.3	24
68	Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. Blood, 2019, 134, 256-256.	0.6	1
69	Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls. Blood, 2019, 134, 700-700.	0.6	3
70	Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy Journal of Clinical Oncology, 2019, 37, 7047-7047.	0.8	1
71	What the Intensivist Needs to Know About Hematopoietic Stem Cell Transplantation?. , 2019, , 1-16.		0
72	Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. Blood, 2019, 134, 3596-3596.	0.6	0

#	Article	IF	CITATIONS
73	A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. Blood, 2019, 134, 257-257.	0.6	1
74	Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. Blood, 2019, 134, 4598-4598.	0.6	0
75	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. Cancer, 2018, 124, 2134-2141.	2.0	30
76	Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2018, 24, 2304-2311.	3.2	11
77	Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 1514-1520.	2.0	61
78	Allogeneic stem cell transplantation for FLT3 mutated acute myeloid leukemia in first complete remission: does age really matter?. Haematologica, 2018, 103, 191-193.	1.7	5
79	Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood, 2018, 131, 1248-1257.	0.6	16
80	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplantation, 2018, 53, 521-534.	1.3	168
81	Haploidentical Transplants for Acute Myeloid Leukemia in Adults. , 2018, , 231-243.		0
82	Haploidentical Transplants for Myeloproliferative Neoplasms. , 2018, , 261-269.		0
83	Prevention and Treatment of Relapse After HLA-Haploidentical Hematopoietic Cell Transplantation. , 2018, , 291-306.		1
84	Future Prospects: Haploidentical Transplantation. , 2018, , 325-337.		0
85	Anti-HLA Antibodies: Assessment and Mitigating Strategies. , 2018, , 127-143.		0
86	Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis. Journal of Cellular Physiology, 2018, 233, 422-433.	2.0	9
87	Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e41-e50.	0.2	17
88	Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 353-358.	2.0	43
89	Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2018, 24, 1232-1236.	2.0	64
90	NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect?. International Journal of Hematology, 2018, 107, 151-156.	0.7	8

#	Article	IF	CITATIONS
91	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 726-733.	2.0	71
92	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematology,the, 2018, 5, e532-e542.	2.2	23
93	Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. Blood Advances, 2018, 2, 1180-1186.	2.5	35
94	Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood, 2018, 131, 2989-2992.	0.6	63
95	An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nature Medicine, 2018, 24, 1036-1046.	15.2	622
96	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. Blood, 2018, 132, 1015-1015.	0.6	2
97	Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Blood, 2018, 132, 971-971.	0.6	29
98	Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study. Blood, 2018, 132, 818-818.	0.6	19
99	Is a matched unrelated donor search needed for all allogeneic transplant candidates?. Blood Advances, 2018, 2, 2254-2261.	2.5	21
100	Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget, 2018, 9, 35611-35622.	0.8	31
101	Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. Blood, 2018, 132, 4607-4607.	0.6	0
102	Stem cell transplantation outcomes in lymphoblastic lymphoma. Leukemia and Lymphoma, 2017, 58, 366-371.	0.6	11
103	Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia. Clinical Cancer Research, 2017, 23, 3385-3395.	3.2	41
104	Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1405-1410.	2.0	5
105	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer, 2017, 123, 3568-3575.	2.0	11
106	Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Cancer, 2017, 123, 2661-2670.	2.0	14
107	Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood, 2017, 129, 3031-3033.	0.6	8
108	Longâ€ŧerm followâ€up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed Tâ€cell chimerism is associated with high relapse risk and inferior survival. British Journal of Haematology, 2017, 177, 567-577.	1.2	7

#	Article	IF	CITATIONS
109	Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. American Journal of Hematology, 2017, 92, 331-337.	2.0	39
110	Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation. Blood, 2017, 130, 1857-1868.	0.6	256
111	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood, 2017, 130, 1156-1164.	0.6	210
112	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 318-324.	2.0	54
113	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biology of Blood and Marrow Transplantation, 2017, 23, 285-292.	2.0	24
114	Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 2166-2171.	2.0	34
115	Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. Journal of Clinical Oncology, 2017, 35, 3002-3009.	0.8	255
116	Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget, 2017, 8, 34552-34564.	0.8	9
117	Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation. Advances in Hematology, 2016, 2016, 1-10.	0.6	45
118	Postâ€ŧransplantation cyclophosphamide versus conventional graftâ€versusâ€host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. British Journal of Haematology, 2016, 173, 444-455.	1.2	61
119	Viral Reactivation in Haploidentical Transplants Using Post-Transplantation Cyclophosphamide – a Single Institution Experience. Biology of Blood and Marrow Transplantation, 2016, 22, S375-S376.	2.0	7
120	Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3 -ITD Allelic Ratio in FLT3 -ITD–Positive Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1218-1226.	2.0	66
121	Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biology of Blood and Marrow Transplantation, 2016, 22, 1290-1298.	2.0	113
122	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood, 2016, 127, 938-947.	0.6	246
123	Results of a 2â€arm, phase 2 clinical trial using postâ€transplantation cyclophosphamide for the prevention of graftâ€versusâ€host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer, 2016, 122, 3316-3326.	2.0	75
124	Reply to: Use of Single-Antigen Flow Beads Assays to Assess Anti-HLA Donor-Specific Antibody Strength. Biology of Blood and Marrow Transplantation, 2016, 22, 395-396.	2.0	0
125	Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biology of Blood and Marrow Transplantation, 2016, 22, 961-965.	2.0	15
126	Optimal Threshold and Time of Absolute Lymphocyte CountÂAssessment for Outcome Prediction after Bone MarrowÂTransplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 505-513.	2.0	28

#	Article	IF	CITATIONS
127	Outcomes of Haploidentical Stem Cell Transplantation forÂLymphoma with Melphalan-Based Conditioning. Biology of Blood and Marrow Transplantation, 2016, 22, 493-498.	2.0	38
128	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival forÂPatients with Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 47-53.	2.0	58
129	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leukemia and Lymphoma, 2016, 57, 1607-1615.	0.6	17
130	Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. Journal of Clinical Investigation, 2016, 126, 3363-3376.	3.9	399
131	Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 2276-2276.	0.6	0
132	Haploidentical Donors in Addition to Transplantation in Chronic Phase Associate with Improved Gvhd-Free Relapse-Free Survival (GRFS) for Patients with Advanced CML. Blood, 2016, 128, 4583-4583.	0.6	0
133	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood, 2015, 126, 1033-1040.	0.6	565
134	Progress in Haploidentical Hematopoietic Stem Cell Transplantation. , 2015, , .		0
135	An overview of conditioning regimens for haploidentical stem cell transplantation with postâ€transplantation cyclophosphamide. American Journal of Hematology, 2015, 90, 541-548.	2.0	31
136	Leukemia cell mobilization with G-CSF plus plerixafor during busulfan–fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplantation, 2015, 50, 939-946.	1.3	32
137	Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1405-1412.	2.0	22
138	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2015, 21, 906-912.	2.0	35
139	Can a Female Donor for a Male Recipient Decrease the Relapse Rate for Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation?. Biology of Blood and Marrow Transplantation, 2015, 21, 713-719.	2.0	36
140	Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse ofÂAcute Myeloid Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2015, 21, 1948-1954.	2.0	63
141	Haploidentical Hematopoietic Stem Cell Transplantation asÂaÂPlatform for Post-Transplantation Cellular Therapy. Biology of Blood and Marrow Transplantation, 2015, 21, 1714-1720.	2.0	30
142	Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1392-1398.	2.0	161
143	"No donor� Consider a haploidentical transplant. Blood Reviews, 2015, 29, 63-70.	2.8	42
144	Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 4321-4321.	0.6	2

#	Article	IF	CITATIONS
145	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. Blood, 2015, 126, 854-854.	0.6	5
146	Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen–Matched Unrelated and Related Donors. Biology of Blood and Marrow Transplantation, 2014, 20, 1975-1981.	2.0	207
147	Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1618-1625.	2.0	46
148	The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 319-326.	0.2	55
149	BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood, 2014, 124, 2306-2312.	0.6	35
150	Feasibility and Outcomes of Haploidentical Transplantation for Elderly Patients with Advanced Hematological Malignancies: The MD Anderson Cancer Center Experience. Blood, 2014, 124, 1245-1245.	0.6	3
151	Autologous stem cell transplantation in dialysis-dependent myeloma patients Journal of Clinical Oncology, 2014, 32, 8601-8601.	0.8	0
152	A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 1453-1458.	2.0	18
153	Donor Selection in T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation: Knowns, Unknowns, and Controversies. Biology of Blood and Marrow Transplantation, 2013, 19, 180-184.	2.0	56
154	Fifty Years of Melphalan Use in Hematopoietic Stem CellÂTransplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 344-356.	2.0	90
155	PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment. Journal of Molecular Medicine, 2013, 91, 1383-1397.	1.7	12
156	Strategies in Haploidentical Stem Cell Transplantation in Adults. Turkish Journal of Haematology, 2013, 30, 342-350.	0.2	3
157	Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS. Blood, 2013, 122, 305-305.	0.6	1
158	Leukemia Stem Cell Marker CD123 (IL-3R alpha) Predicts Minimal Residual Disease and Relapse, Providing a Valid Target For SL-101 In Acute Myeloid Leukemia With FLT3-ITD Mutations. Blood, 2013, 122, 359-359.	0.6	10
159	Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML) Journal of Clinical Oncology, 2013, 31, 7010-7010.	0.8	0
160	Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR). Blood, 2013, 122, 2142-2142.	0.6	0
161	Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leukemia and Lymphoma, 2012, 53, 901-906.	0.6	20
162	NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. Immunotherapy, 2012, 4, 305-313.	1.0	23

#	Article	IF	CITATIONS
163	Progress in Haploidentical Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 372-380.	2.0	39
164	Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1835-1844.	2.0	227
165	A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. Blood. 2012, 120, 4200-4200.	0.6	5
166	Reconstitution of Lymphocyte Subsets and Outcomes After Matched and Mismatched Hematopoietic Stem-Cell Transplantation. Blood, 2012, 120, 4485-4485.	0.6	0
167	Relevance and Factors Predicting for Early Lymphocyte Recovery After Allogeneic Bone Marrow Stem Cell Transplantation (BMT) Blood, 2012, 120, 3053-3053.	0.6	0
168	Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared with One Human Leukocyte Antigen Mismatched Related Donors Using HLA Typing at 10 Loci. Biology of Blood and Marrow Transplantation, 2011, 17, 923-929.	2.0	22
169	Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1169-1175.	2.0	44
170	Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood, 2011, 118, 5957-5964.	0.6	197
171	Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd. Blood, 2011, 118, 894-894.	0.6	2
172	Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. Blood, 2011, 118, 2006-2006.	0.6	0
173	Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation. American Journal of Blood Research, 2011, 1, 98-105.	0.6	22
174	Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation. Biology of Blood and Marrow Transplantation, 2010, 16, 555-559.	2.0	46
175	Busulfan in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 523-536.	2.0	196
176	Aging, Acute Myelogenous Leukemia, and Allogeneic Transplantation: Do They Belong in the Same Sentence?. Clinical Lymphoma and Myeloma, 2009, 9, 289-297.	1.4	8
177	High Risk of Graft Failure in Patients With Anti-HLA Antibodies Undergoing Haploidentical Stem-Cell Transplantation. Transplantation, 2009, 88, 1019-1024.	0.5	236
178	Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL) Blood, 2009, 114, 3213-3213.	0.6	0
179	Sustained Engraftment Using Fludarabine, Melphalan and Thiotepa Conditioning for Haploidentical Stem Cell Transplantation Blood, 2007, 110, 5081-5081.	0.6	2
180	Donor-specific anti-human leukocyte antigen antibodies and risk of graft failure after hematopoietic cell transplants. , 0, , 73-78.		0

#	Article	IF	CITATIONS
181	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplantation, 0, , .	1.3	3
182	SIRPα Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. Frontiers in Immunology, 0, 13, .	2.2	0